[Effects of cytokines on the immunogenic properties of hepatitis A vaccine].
Avdeeva. Zh I ZhI; Akol'zina. S E SE; Alpatova. N A NA; Medunitsyn. N V NV
Key Findings
- Cytokines act as strong adjuvants for hepatitis A vaccine in guinea pigs
- Thymosin‑alpha‑1 was one of the most effective cytokines, boosting antibody titers 2‑10‑fold
- All animals receiving the cytokine‑enhanced vaccine seroconverted, versus 75‑89% in controls
Practical Outcomes
- The data suggest thymosin‑alpha‑1 could potentially improve vaccine efficacy, but the evidence is limited to animal studies. Biohackers should treat this as a hypothesis‑generating finding and await human trials before adding it to personal vaccination protocols.
Summary
In guinea‑pig experiments, adding certain cytokines—including the peptide thymosin‑alpha‑1—to a hepatitis A vaccine dramatically increased the animals' antibody response, achieving up to ten‑times higher antibody levels and 100% seroconversion compared with the vaccine alone.
Abstract
Cytokines were found, in experiments with guinea pigs, to have a stimulating action on the immunogenic potency of hepatitis A vaccine (Hep-A-in-Vac). The most pronounced effects were produced by rhIL-1b, rhTNF-alpha, thymosin-a1, the "neothym" hybrid protein and immunophan. Injections of cytokines as of adjuvants stimulated the formation of antibodies titers that exceeded 2-10-fold those observed in control animals immunized by Hep-A-in-Vac alone. Immunization of guinea pigs made alongside with injections of the above cytokines ensured a 100% seroconversion in animals after the administration of drugs was completed. The number of seropositive animals in the control group was 75-89%.
Study Information
pubmed
2005